Pluri Inc. (PLUR) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Pluri Inc. on April 17, 2025, regarding an event that occurred on April 15, 2025. The Company, incorporated in Nevada and headquartered in Haifa, Israel, operates in the biotechnology sector with a focus on cell therapy development.
Key Financial Metrics
The filing does not provide specific financial statements, revenue, profit, cash flow, or liquidity metrics for the reporting period. The only financial figure disclosed relates to a terminated contract valued at $4.2 million over three years.
Material Changes and Events
- Contract Termination: On April 15, 2025, Pluri Biotech Ltd., a wholly-owned subsidiary, received a formal notice of termination from the U.S. National Institute of Allergy and Infectious Diseases (NIAID).
- Reason for Termination: The contract was terminated for the Government's convenience, effective immediately.
- Program Impact: The terminated agreement, originally awarded on July 11, 2023, was intended to support the development of PLX-R18 cell therapy for Hematopoietic Acute Radiation Syndrome (H-ARS). It involved collaboration with the U.S. Department of Defense Armed Forces Radiobiology Research Institute (AFRRI) and the Uniformed Services University of Health Sciences (USUHS).
Management Commentary, Risks, and Outlook
Management believes the termination may reflect broader federal budgetary and administrative adjustments affecting multiple health-related agencies, including the National Institutes of Health. The Company is monitoring these developments to assess potential implications for its ongoing programs. No specific guidance or revised outlook was provided in this filing.
Key Facts for Investor Verification
- Verify the total amount of revenue recognized from the terminated $4.2 million contract prior to April 15, 2025.
- Assess the impact of the termination on the Company's cash runway and liquidity position.
- Determine if other government-funded contracts or programs are at risk due to the cited federal budgetary adjustments.
- Review the status of the PLX-R18 cell therapy program and whether alternative funding sources are being pursued.